CD52 Shielding Platform

About Cimeio Therapeutics

Cimeio Therapeutics is developing a groundbreaking platform that pairs gene-edited, 'shielded' cells with potent immunotherapies to create curative treatments for hematologic diseases. Its core innovation involves editing cell surface proteins to maintain function while making them invisible to paired therapies like antibodies, ADCs, and CAR-T cells, allowing for targeted conditioning and disease eradication. The company has validated its approach with a high-profile Nature publication and secured a significant partnership with Kyowa Kirin valued at up to $300 million, positioning it as a leader in next-generation cell and gene therapies.

Therapeutic Areas